Werewolf Therapeutics Shares Jump on Encouraging Trial Data
By Dean Seal Shares of Werewolf Therapeutics shot higher after the company presented Phase 1 trial data establishing proof of mechanism for its lead clinical...
Daniel Hicklin Werewolf Therapeutics Executive Daniel Hicklin Dean Seal Article Normal Biotechnology Services
Source: marketwatch.com